PDCD1 and cholangiocarcinoma: Moreover, the CK2 inhibitors used in our study, CX4945, has been approved by the FDA for the treatment of cholangiocarcinoma and has demonstrated promising anti‐tumor activity in clinical settings.[35] Therefore, our findings provide a strong experimental foundation for the combined application of CK2 inhibitors and anti‐PD‐1 therapy in clinical settings.